Burkitt, D. A sarcoma involving the jaws in African children. Br. J. Surg. 46, 218–223 (1958).
Magrath, I. Denis Burkitt and the African lymphoma. Ecancermedicalscience 3, 159 (2009).
Davies, J. N. P. et al. Cancer in an African community, 1897–1956: an analysis of the records of Mengo Hospital, Kampala, Uganda: Part I. Br. Med. J. 1, 259–264 (1964).
Wright, D. H. Burkitt’s tumour. A post‐mortem study of 50 cases. Br. J. Surg. 51, 245–251 (1964).
Elmes, B. G. T. & Baldwin, R. B. T. Malignant disease in Nigeria: an analysis of a thousand tumours. Ann. Trop. Med. Parasitol. 41, 321–328 (1947).
O’Conor, G. T. & Davies, J. N. P. Malignant tumors in African children. With special reference to malignant lymphoma. J. Pediatr. 56, 526–535 (1960).
Brown, J. B. & O’Keefe, C. Brief communications: Sarcoma of the ovary with unusual oral metastases. Ann. Surg. 87, 467–476 (1928).
Epstein, M. A. & Barr, Y. M. Cultivation in vitro of human lymphoblasts from Burkitt’s malignant lymphoma. Lancet 283, 252–253 (1964).
Stewart, S. E., Lovelace, E., Whang, J. J. & Ngu, V. A. Burkitt tumor: tissue culture, cytogenetic and virus studies. J. Natl Cancer Inst. 34, 319–327 (1965).
Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt’s Lymphoma. Lancet 283, 702–703 (1964).
Manolov, G. & Manolova, Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 237, 33–34 (1972). This study identifies for the first time the derivative chromosome 14 as a consequence of translocation t(8;14) in Burkitt lymphoma, highlighting the relevance of genetic abnormalities in this lymphoma.
Zech, L., Haglund, U., Nilsson, K. & Klein, G. Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with Burkitt and non‐Burkitt lymphomas. Int. J. Cancer 17, 47–56 (1976).
Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824–7827 (1982). Molecular study showing that MYC oncogene is the gene involved in the chromosomal aberration t(8;14) in BL.
Boerma, E. G., Siebert, R., Kluin, P. M. & Baudis, M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 23, 225–234 (2009).
Dalla-Favera, R. et al. Mechanism of activation and biological role of the c‐myc oncogene in B‐cell lymphomagenesis. Ann. NY Acad. Sci. 511, 207–218 (1987).
Swerdlow, S.H. et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC, 2017).
Geser, A. et al. Epstein-Barr virus markers in a series of Burkitt’s lymphomas from the West Nile District, Uganda. Eur. J. Cancer Clin. Oncol. 19, 1393–1404 (1983).
Grande, B. M. et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 133, 1313–1324 (2019). A comprehensive molecular analysis of both EBV+and EBV–BL demonstrated a link between EBV+BL and mutation patterns indicative of aberrant AID expression and function.
Kaymaz, Y. et al. Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences. Mol. Cancer Res. 15, 563–576 (2017).
Abate, F. et al. Distinct viral and mutational spectrum of endemic Burkitt lymphoma. PLoS Pathog. 11, e1005158 (2015).
Leoncini, L. Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes. Br. J. Haematol. 196, 468–470 (2022).
Rochford, R. Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants. Ann. Lymphoma 5, 22 (2021).
Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720–1748 (2022).
Haddow, A. J. An improved map for the study of Burkitt’s lymphoma syndrome in Africa. East. Afr. Med. J. 40, 429–432 (1963).
Burkitt, D. A. “Tumour safari” in East and Central Africa. Br. J. Cancer 16, 379–386 (1962).
Burkitt, D. A children’s cancer dependent on climatic factors. Nature 194, 232–234 (1962).
Kafuko, G. W. & Burkitt, D. P. Burkitt’s lymphoma and malaria. Int. J. Cancer 6, 1–9 (1970).
Rainey, J. J. et al. Spatial clustering of endemic Burkitt’s lymphoma in high-risk regions of Kenya. Int. J. Cancer 120, 121–127 (2007).
Liao, H.-M. et al. Epstein–Barr virus in Burkitt lymphoma in Africa reveals a limited set of whole genome and LMP-1 sequence patterns: analysis of archival datasets and field samples from Uganda, Tanzania, and Kenya. Front. Oncol. 12, 812224 (2022).
Anwar, N. et al. The investigation of Epstein–Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt. Epidemiologic correlations. Cancer 76, 1245–1252 (1995).
Hassan, R. et al. Clinical and demographic characteristics of Epstein–Barr virus-associated childhood Burkitt’s lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region. Haematologica 93, 780–783 (2008).
Queiroga, E. M. et al. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am. J. Clin. Pathol. 130, 946–956 (2008).
Mbulaiteye, S. M. et al. Epstein–Barr virus patterns in US Burkitt lymphoma tumors from the SEER Residual Tissue Repository during 1979–2009. APMIS 122, 5–15 (2014).
Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. Ca. Cancer J. Clin. 66, 443–459 (2016).
Dunford, A. et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat. Genet. 49, 10–16 (2017).
Richter, J. et al. Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. Br. J. Haematol. https://doi.org/10.1111/bjh.17874 (2021).
Zhang, X. et al. Sex- and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities. Nat. Aging 1, 87–100 (2021).
Mbulaiteye, S. M. et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt’s lymphoma incidence diagnosed in four continents, excluding Africa. Am. J. Hematol. 87, 573–578 (2012).
Mbulaiteye, S. M. et al. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int. J. Cancer 126, 1732–1739 (2010). This was the first paper to report multimodal patterns of Burkitt lymphoma the US, suggesting that the molecular forms of Burkitt lymphoma may vary with age at diagnosis, and that mortality patterns vary with age.
Greenspan, D. et al. Diffuse, undifferentiated non-Hodgkins lymphoma among homosexual males – United States. MMWR Morb. Mortal. Wkly. Rep. 31, 277–279 (1982).
Ziegler, J. L. et al. High-grade non-Hodgkin’s lymphoma in patients with AIDS. Ann. NY Acad. Sci. 437, 412–419 (1984).
Serraino, D. et al. The epidemiology of AIDS-associated non-Hodgkin’s lymphoma in the World Health Organization European Region. Br. J. Cancer 66, 912–916 (1992).
Mbulaiteye, S. M. & Devesa, S. S. Burkitt lymphoma incidence in five continents. Hemato 3, 434–453 (2022).
Mbulaiteye, S. M. & Anderson, W. F. Age-related heterogeneity of Burkitt lymphoma. Br. J. Haematol. 180, 153–155 (2018).
Roschewski, M. et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J. Clin. Oncol. 38, 2519–2529 (2020). A multicentre prospective study demonstrating the safety and efficacy of low-intensity therapy with dose-adjusted EPOCH-R in adults with Burkitt lymphoma.
Dunleavy, K. et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N. Engl. J. Med. 369, 1915–1925 (2013).
Roithmann, S. et al. HTV-associated non-Hodgkin’s lymphomas: clinical characteristics and outcome. The experience of the French registry of HIV-associated tumors. Ann. Oncol. 2, 289–295 (1991).
Worch, J., Rohde, M. & Burkhardt, B. Mature B-cell lymphoma and leukemia in children and adolescents – review of standard chemotherapy regimen and perspectives. Pediatr. Hematol. Oncol. 30, 465–483 (2013).
Mbulaiteye, S. M. et al. African Burkitt’s lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate? Lancet 375, 1661–1663 (2010).
Ozuah, N. W., Lubega, J., Allen, C. E. & El-Mallawany, N. K. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv. 4, 4007–4019 (2020). A retrospective study demonstrating the challenges of delivering effective therapy in resource-restricted areas of the world such as sub-Saharan Africa.
Costa, L. J., Xavier, A. C., Wahlquist, A. E. & Hill, E. G. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 121, 4861–4866 (2013).
Noy, A. et al. AMC 048: Modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood 126, 160–166 (2015). A multicenter prospective study demonstrating the feasibility and efficacy of highly dose-intensive chemotherapy with CODOX-M/IVAC in adults with HIV-associated Burkitt lymphoma.
Joko-Fru, W. Y. et al. Survival from childhood cancers in Eastern Africa: a population-based registry study. Int. J. Cancer 143, 2409–2415 (2018).
McGoldrick, S. M. et al. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda. Pediatr. Blood Cancer 66, e27813 (2019).
Kazembe, P., Hesseling, P. B., Griffin, B. E., Lampert, I. & Wessels, G. Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy. Med. Pediatr. Oncol. 40, 23–25 (2003).
Olweny, C. L. M. et al. Long‐term experience with Burkitt’s lymphoma in Uganda. Int. J. Cancer 26, 261–266 (1980).
Clifford, P., Singh, S., Stjernswärd, J. & Klein, G. Long-term survival of patients with Burkitt’s lymphoma: an assessment of treatment and other factors which may relate to survival. Cancer Res. 27, 2578–2615 (1967).
Rochford, R., Cannon, M. J. & Moormann, A. M. Endemic Burkitt’s lymphoma: a polymicrobial disease? Nat. Rev. Microbiol. 3, 182–187 (2005).
Morrow, R. H. in Burkitt’s Lymphoma: A Human Cancer Model No. 60 (eds Lenoir, G. M., O‘Conor, G.T. & Olweny, C. L. M.) 177–186 (IARC, 1985).
Carpenter, L. M. et al. Antibodies against malaria and Epstein–Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int. J. Cancer 122, 1319–1323 (2008).
留言 (0)